Join the club for FREE to access the whole archive and other member benefits.

Unity's senolytic drug reports positive phase 1 data in eye disease patients


Key points from article :

Unity Biotechnology reports positive data in phase 1 study in patients with advanced vascular eye disease.

Its small-molecule inhibitor of Bcl-xL, a senolytic therapeutic, was well tolerated in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD).

Study of UBX1325 was conducted in patients for whom anti-VEGF therapy was not beneficial.

Improvements in retinal structure and vision, although this was in just 12 patients.

"This drug has the potential for a monotherapy, in combination with anti-VEGF, or for people who are sub optimal responders to anti-VEGF," - Anirvan Ghosh, CEO of Unity.

Phase 2a study evaluating the safety and efficacy in a broader populations of DME patients.

"As we go to a broader patient population that are less advanced, we might see even greater efficacy," - Ghosh.

In the next 18 to 20 months, Unity will begin exploring other systems that have strong evidence of senescence biology.

Begun phase 2 trial including patients with early stage of disease to test its safety and effectiveness

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company Representative

Chief Executive Officer at UNITY Biotechnology.


Biotechnology company devoted to research of restoring human health